Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: KIT 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
2 Acute myeloid leukemia 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
3 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
4 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
5 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
6 Adipocytokine signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
7 African trypanosomiasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
8 African trypanosomiasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
13 Alcoholic liver disease 💬
 1件: C5 💬 Nomacopan 💬 Nomacopan 3件: 62, 109, 162 💬
14 Alcoholic liver disease 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
15 Alcoholic liver disease 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
16 Alcoholic liver disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
17 Allograft rejection 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
18 Allograft rejection 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
19 Allograft rejection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
20 Alzheimer disease 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
21 Alzheimer disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
22 Amoebiasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
23 Amoebiasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
24 Amphetamine addiction 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
25 AMPK signaling pathway 💬
 1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
26 Amyotrophic lateral sclerosis 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
27 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
28 Antigen processing and presentation 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
29 Apoptosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
30 Asthma 💬
 1件: FCER1A 💬 Omalizumab 💬 Omalizumab 7件: 46, 53, 65, 98, 162, 226, 299 💬
31 Asthma 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
32 Asthma 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
33 Autoimmune thyroid disease 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
34 Axon guidance 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
35 Axon guidance 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
36 Axon guidance 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
37 B cell receptor signaling pathway 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
38 Bile secretion 💬
 1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
39 Breast cancer 💬
 1件: KIT 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
40 Breast cancer 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
41 C-type lectin receptor signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
42 C-type lectin receptor signaling pathway 💬
 1件: IL23A 💬 Tildrakizumab 💬 Tildrakizumab 2件: 162, 271 💬
43 C-type lectin receptor signaling pathway 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
44 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
45 Calcium signaling pathway 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
46 Calcium signaling pathway 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
47 Calcium signaling pathway 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
48 cAMP signaling pathway 💬
 4件: PDE4, PDE4, PDE4, PDE4 💬 Apremilast 💬 Apremilast 8件: 36, 46, 50, 56, 97, 107, 162, 271 💬
49 Cell cycle 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
50 Cell cycle 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
51 Cellular senescence 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
52 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
53 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
54 cGMP-PKG signaling pathway 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
55 Chagas disease 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
56 Chagas disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
57 Chemical carcinogenesis - reactive oxygen species 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
58 Chemical carcinogenesis - reactive oxygen species 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
59 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
60 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
61 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
62 Chemical carcinogenesis - receptor activation 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 23件:  6 , 11, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 65, 84, 85, 96, 97, 98, 162, 228, 271, 298, 299 💬
63 Chemokine signaling pathway 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
64 Chemokine signaling pathway 💬
 2件: JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
65 Chemokine signaling pathway 💬
 2件: JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
66 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
67 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
68 Cholinergic synapse 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
69 Cholinergic synapse 💬
 1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
70 Cholinergic synapse 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
71 Chronic myeloid leukemia 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
72 Chronic myeloid leukemia 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
73 Complement and coagulation cascades 💬
 1件: C5 💬 Nomacopan 💬 Nomacopan 3件: 62, 109, 162 💬
74 Coronavirus disease - COVID-19 💬
 1件: C5 💬 Nomacopan 💬 Nomacopan 3件: 62, 109, 162 💬
75 Coronavirus disease - COVID-19 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
76 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
77 Coronavirus disease - COVID-19 💬
 2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
78 Coronavirus disease - COVID-19 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
79 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
80 Cytokine-cytokine receptor interaction 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
81 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
82 Cytokine-cytokine receptor interaction 💬
 1件: IL23A 💬 Tildrakizumab 💬 Tildrakizumab 2件: 162, 271 💬
83 Cytokine-cytokine receptor interaction 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
84 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
85 Cytokine-cytokine receptor interaction 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
86 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
87 Dilated cardiomyopathy 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
88 Dopaminergic synapse 💬
 3件: PPP3C, PPP3C, PPP3C 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
89 Drug metabolism - other enzymes 💬
 2件: IMPDH, IMPDH 💬 Mycophenolate sodium 💬 Mycophenolic acid 37件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 84, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
90 Drug metabolism - other enzymes 💬
 2件: IMPDH, IMPDH 💬 Mycophenolic acid 💬 Mycophenolic acid 37件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 84, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
91 Efferocytosis 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
92 Efferocytosis 💬
 1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
93 Efferocytosis 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
94 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 23件:  6 , 11, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 65, 84, 85, 96, 97, 98, 162, 228, 271, 298, 299 💬
95 Endocytosis 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
96 Endocytosis 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
97 Epstein-Barr virus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
98 Epstein-Barr virus infection 💬
 3件: JAK1, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
99 Epstein-Barr virus infection 💬
 3件: JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
100 Epstein-Barr virus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
101 ErbB signaling pathway 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
102 ErbB signaling pathway 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
103 Fc epsilon RI signaling pathway 💬
 1件: FCER1A 💬 Omalizumab 💬 Omalizumab 7件: 46, 53, 65, 98, 162, 226, 299 💬
104 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
105 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
106 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
107 Focal adhesion 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
108 Focal adhesion 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
109 Folate biosynthesis 💬
 2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
110 Folate biosynthesis 💬
 2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
111 Folate transport and metabolism 💬
 2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
112 Folate transport and metabolism 💬
 2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
113 Gap junction 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
114 Gap junction 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
115 Glioma 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
116 Glioma 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
117 Glucagon signaling pathway 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
118 Glutamatergic synapse 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
119 Graft-versus-host disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
120 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
121 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
122 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
123 Hematopoietic cell lineage 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
124 Hematopoietic cell lineage 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
125 Hematopoietic cell lineage 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
126 Hematopoietic cell lineage 💬
 1件: KIT 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
127 Hematopoietic cell lineage 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
128 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 Rituximab 💬 Rituximab 52件: 11, 13, 14, 19, 26, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 172, 220, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
129 Hematopoietic cell lineage 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
130 Hepatitis B 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
131 Hepatitis B 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
132 Hepatitis B 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
133 Hepatitis B 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
134 Hepatitis C 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
135 Hepatitis C 💬
 2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
136 Hepatitis C 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
137 Hepatitis C 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
138 Herpes simplex virus 1 infection 💬
 1件: C5 💬 Nomacopan 💬 Nomacopan 3件: 62, 109, 162 💬
139 Herpes simplex virus 1 infection 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
140 Herpes simplex virus 1 infection 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
141 Herpes simplex virus 1 infection 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
142 Herpes simplex virus 1 infection 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
143 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
144 Hormone signaling 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
145 Hormone signaling 💬
 1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
146 Hormone signaling 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
147 Human cytomegalovirus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
148 Human cytomegalovirus infection 💬
 1件: JAK1 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
149 Human cytomegalovirus infection 💬
 1件: JAK1 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
150 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
151 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
152 Human cytomegalovirus infection 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
153 Human cytomegalovirus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
154 Human immunodeficiency virus 1 infection 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
155 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
156 Human papillomavirus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
157 Human papillomavirus infection 💬
 2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
158 Human papillomavirus infection 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
159 Human papillomavirus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
160 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
161 Human T-cell leukemia virus 1 infection 💬
 2件: JAK1, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
162 Human T-cell leukemia virus 1 infection 💬
 2件: JAK1, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
163 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
164 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
165 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
166 IL-17 signaling pathway 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
167 IL-17 signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
168 IL-17 signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
169 Inflammatory bowel disease 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
170 Inflammatory bowel disease 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
171 Inflammatory bowel disease 💬
 1件: IL23A 💬 Tildrakizumab 💬 Tildrakizumab 2件: 162, 271 💬
172 Inflammatory bowel disease 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
173 Inflammatory bowel disease 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
174 Inflammatory bowel disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
175 Influenza A 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
176 Influenza A 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
177 Influenza A 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
178 Influenza A 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
179 Influenza A 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
180 Insulin resistance 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
181 Intestinal immune network for IgA production 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
182 JAK-STAT signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
183 JAK-STAT signaling pathway 💬
 1件: IL23A 💬 Tildrakizumab 💬 Tildrakizumab 2件: 162, 271 💬
184 JAK-STAT signaling pathway 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
185 JAK-STAT signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
186 JAK-STAT signaling pathway 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
187 JAK-STAT signaling pathway 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
188 JAK-STAT signaling pathway 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
189 JAK-STAT signaling pathway 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
190 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
191 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
192 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
193 Kaposi sarcoma-associated herpesvirus infection 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
194 Kaposi sarcoma-associated herpesvirus infection 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
195 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
196 Legionellosis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
197 Legionellosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
198 Leishmaniasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
199 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
200 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
201 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
202 Leishmaniasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
203 Lipid and atherosclerosis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
204 Lipid and atherosclerosis 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
205 Lipid and atherosclerosis 💬
 1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
206 Lipid and atherosclerosis 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
207 Lipid and atherosclerosis 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
208 Lipid and atherosclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
209 Long-term potentiation 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
210 Malaria 💬
 1件: IL12A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
211 Malaria 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
212 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
213 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
214 MAPK signaling pathway 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
215 MAPK signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
216 Measles 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
217 Measles 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
218 Measles 💬
 3件: JAK1, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
219 Measles 💬
 3件: JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
220 Melanogenesis 💬
 1件: KIT 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
221 Melanogenesis 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
222 Melanoma 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
223 Melanoma 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
224 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
225 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
226 Mineral absorption 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 23件:  6 , 11, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 65, 84, 85, 96, 97, 98, 162, 228, 271, 298, 299 💬
227 Morphine addiction 💬
 4件: PDE4, PDE4, PDE4, PDE4 💬 Apremilast 💬 Apremilast 8件: 36, 46, 50, 56, 97, 107, 162, 271 💬
228 mTOR signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
229 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
230 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
231 Necroptosis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
232 Necroptosis 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
233 Necroptosis 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
234 Necroptosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
235 Neuroactive ligand-receptor interaction 💬
 1件: C5 💬 Nomacopan 💬 Nomacopan 3件: 62, 109, 162 💬
236 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Clobetasol 💬 Clobetasol 4件: 39, 46, 51, 162 💬
237 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Clobetasol propionate 💬 Clobetasol propionate 2件: 46, 162 💬
238 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Dexamethasone 💬 Dexamethasone 25件: 13, 14, 16, 19, 28, 35, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 296, 299, 331 💬
239 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Dexamethasone sodium phosphate 💬 Dexamethasone 25件: 13, 14, 16, 19, 28, 35, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 296, 299, 331 💬
240 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Dexamethasone phosphate 💬 Dexamethasone 25件: 13, 14, 16, 19, 28, 35, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 296, 299, 331 💬
241 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Halometasone 💬 Halometasone 1件: 162 💬
242 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Methylprednisolone 💬 Methylprednisolone 48件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 127, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬
243 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Methylprednisolone acetate 💬 Methylprednisolone 48件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 127, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬
244 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Mometasone 💬 Mometasone 2件: 98, 162 💬
245 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Mometasone furoate 💬 Mometasone furoate 2件: 98, 162 💬
246 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Mometasone furoate hydrate 💬 Mometasone furoate 2件: 98, 162 💬
247 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisolone 💬 Prednisolone 41件:  3 , 11, 13, 14, 18, 25, 26, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 60, 61, 63, 64, 66, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 251, 269, 271, 296, 299, 300 💬
248 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisone 💬 Prednisone 54件:  2 , 11, 13, 14, 18, 19, 26, 28, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 60, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 90, 93, 95, 96, 97, 113, 145, 162, 164, 205, 222, 224, 228, 251, 269, 283, 285, 288, 299, 300, 303, 307, 331 💬
249 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisone acetate 💬 Prednisone acetate 9件: 35, 40, 41, 46, 49, 63, 162, 222, 224 💬
250 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
251 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
252 Neutrophil extracellular trap formation 💬
 1件: C5 💬 Nomacopan 💬 Nomacopan 3件: 62, 109, 162 💬
253 NF-kappa B signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
254 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
255 NOD-like receptor signaling pathway 💬
 2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
256 NOD-like receptor signaling pathway 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
257 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
258 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
259 Non-small cell lung cancer 💬
 1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
260 Non-small cell lung cancer 💬
 1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
261 One carbon pool by folate 💬
 2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
262 One carbon pool by folate 💬
 2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
263 Oocyte meiosis 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
264 Osteoclast differentiation 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
265 Osteoclast differentiation 💬
 2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
266 Osteoclast differentiation 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
267 Osteoclast differentiation 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
268 Osteoclast differentiation 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
269 Oxytocin signaling pathway 💬
 5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
270 Pancreatic cancer 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
271 Pancreatic cancer 💬
 1件: JAK1 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
272 Pancreatic cancer 💬
 1件: JAK1 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
273 Parathyroid hormone synthesis, secretion and action 💬
 4件: PDE4, PDE4, PDE4, PDE4 💬 Apremilast 💬 Apremilast 8件: 36, 46, 50, 56, 97, 107, 162, 271 💬
274 Parathyroid hormone synthesis, secretion and action 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 23件:  6 , 11, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 65, 84, 85, 96, 97, 98, 162, 228, 271, 298, 299 💬
275 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
276 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
277 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
278 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
279 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
280 Pathways in cancer 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
281 Pathways in cancer 💬
 1件: IL23A 💬 Tildrakizumab 💬 Tildrakizumab 2件: 162, 271 💬
282 Pathways in cancer 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬